Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating
/ administration & dosage
Chemical and Drug Induced Liver Injury
/ epidemiology
Female
Humans
Male
Mesothelioma, Malignant
/ drug therapy
Middle Aged
Pleural Neoplasms
/ drug therapy
Progression-Free Survival
Survival Rate
Trabectedin
/ administration & dosage
Treatment Outcome
Tumor Microenvironment
Hepatotoxicity
Mesothelioma
Nonepithelioid
Second-line treatment
Trabectedin
Journal
Clinical lung cancer
ISSN: 1938-0690
Titre abrégé: Clin Lung Cancer
Pays: United States
ID NLM: 100893225
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
31
03
2020
revised:
15
06
2020
accepted:
29
06
2020
pubmed:
1
8
2020
medline:
7
1
2022
entrez:
1
8
2020
Statut:
ppublish
Résumé
New therapeutic approaches in unresectable malignant pleural mesothelioma (MPM) are eagerly awaited. Trabectedin is an antitumor agent with an effect on cancer cell proliferation and a modulating action on tumor microenvironment. The ATREUS study explored the activity and safety of trabectedin in patients with unresectable MPM. Epithelioid patients with MPM received trabectedin as second-line while biphasic/sarcomatoid patients with MPM as first- or second-line therapy. Treatment was given intravenously at an initially planned dose of 1.3 mg/m Overall, 78 patients (54%) had epithelioid and 67 (46%) nonepithelioid MPM. PFS Trabectedin showed modest clinical activity, at the expense of relevant liver toxicity. Further development of this drug in MPM at full doses is not warranted.
Identifiants
pubmed: 32732073
pii: S1525-7304(20)30222-9
doi: 10.1016/j.cllc.2020.06.028
pii:
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Trabectedin
ID0YZQ2TCP
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-370.e3Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.